At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Placebo 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR)
In Brief
A Phase 4 clinical trial evaluating Mirabegron and Placebo for Multiple Sclerosis. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if treatment with Mirabegron will improve urinary urgency control beyond that achieved with pelvic floor exercises alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsAstellas Pharma Inc
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartMay 2014
Primary CompletionApr 2019
Study CompletionJun 2019
TodayJul 2026
First PostedMar 13, 2014
Enrollment StartMay 1, 2014
Primary CompletionApr 1, 2019
Study CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 12.3 years ago
Interventions
Mirabegrondrug
see detailed information in associated Arm Description
Placebodrug
Sugar pill manufactured to mimic Mirabegron 25mg tablet.